AEON Biopharma / Priveterra Acquisition Corp. — Q2 2023 Form 10-Q Summary
Important context: The filing is by Priveterra Acquisition Corp., a blank-check company pursuing a merger with AEON Biopharma, Inc.; it is not AEON’s operating-company quarterly report. The reporting period ended June 30, 2023. Priveterra reported no operating revenue or business operations before completing a business combination.
Financial performance and position
- Revenue: None. Priveterra had not commenced operations and expected no operating revenue before a business combination.
- Q2 2023: Operating costs were $3.53 million and net loss was $3.94 million, versus operating costs of $0.43 million and net income of $1.87 million in Q2 2022. The 2023 loss included a $0.52 million unrealized warrant loss and $0.20 million of trust-account interest income.
- First half 2023: Operating costs were $5.27 million and net loss was $4.33 million, compared with operating costs of $0.82 million and net income of $4.64 million in first-half 2022. First-half 2023 results included $1.90 million of trust interest, a $0.67 million unrealized warrant loss, and a $0.20 million gain from forgiveness of an underwriting fee.
- Cash flow: Cash used in operations was $1.57 million for the six months ended June 30, 2023, versus $0.57 million in 2022. Ending operating cash was $441,377, compared with $7,758 a year earlier.
- Liquidity and liabilities: The trust account held $21.19 million, down from $279.38 million at December 31, 2022, primarily reflecting $259.00 million paid for share redemptions. Current liabilities were $9.46 million; the filing reported a working capital deficit of $8.87 million, excluding taxes payable funded from trust earnings. A $1.00 million non-interest-bearing sponsor note was outstanding. Deferred underwriting fees were $1.26 million.
- Equity and redemption: 2,002,272 Class A shares remained subject to possible redemption at June 30, 2023, after holders redeemed 25,597,728 shares in February. Stockholders’ deficit was $11.46 million.
Material changes, outlook, and risks
- Operating costs rose substantially year over year, while results shifted from income to loss. Results are materially affected by noncash warrant fair-value changes and trust-account interest, not operating business performance.
- The proposed merger agreement provides for AEON equity consideration based on an implied $165 million AEON equity value; 809,000 shares were to be held back in connection with certain convertible notes. The filing does not provide operating guidance for AEON.
- Priveterra’s business-combination deadline was extended to August 11, 2023. Management said it intended to complete the transaction before then, but concluded that liquidity constraints and the potential mandatory liquidation raised substantial doubt about the company’s ability to continue as a going concern.
- After quarter-end, a July 3 special meeting took place; the filing reports attendance but does not establish in this excerpt that the merger closed. On July 11, the company announced plans, subject to closing, to move the post-combination listing to NYSE American under “AEON.”
- A purported stockholder lawsuit and several demand letters alleged omissions in the merger registration statement and sought corrective disclosures. The filing’s “Legal Proceedings” item says “None,” while the notes describe these allegations; investors should clarify their status.
- The company accrued $424,059 of excise tax related to redemptions, subject to possible offset by share issuances and uncertainty about application of the tax. The filing also reports a material weakness in internal control over financial reporting involving accounting for extinguishment of a contingent obligation; management described remediation efforts.
Key facts for investors to verify
- Whether the AEON business combination closed by the August 11, 2023 deadline, and the final cash, redemptions, financing, and share-count terms.
- AEON’s standalone operating results, cash runway, debt and convertible-note obligations; this filing does not supply those operating-company metrics.
- The status and potential financial impact of the stockholder lawsuit, demand letters, remaining underwriting fee, and excise-tax liability.
- Whether Priveterra’s disclosed material weakness was remediated and whether any further control deficiencies were identified.